JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB20897

Anti-HLA-DP antibody [B7/21]

Be the first to review this product! Submit a review

|

(26 Publications)

Mouse Monoclonal DPA1 antibody. Suitable for ICC and reacts with Human samples. Cited in 26 publications.

View Alternative Names

HLA-DP1A, HLASB, HLA-DPA1, DP(W3), DP(W4), HLA-SB alpha chain, MHC class II DP3-alpha, MHC class II DPA1

1 Images
Immunocytochemistry - Anti-HLA-DP antibody [B7/21] (AB20897)
  • ICC

Lab

Immunocytochemistry - Anti-HLA-DP antibody [B7/21] (AB20897)

ab20897 staining HLA-DP in RAMOS cells. The cells were fixed with 100% methanol (5 min), permeabilized with 0.1% PBS-Tween for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at 4°C with ab20897 at 5μg/ml and ab6046, Rabbit polyclonal to beta Tubulin - Loading Control. Cells were then incubated with ab150117, Goat polyclonal Secondary Antibody to Mouse IgG H&L (Alexa Fluor® 488) preadsorbed at 1/1000 dilution (shown in green) and ab150080, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (Alexa Fluor® 594) at 1/1000 dilution (shown in pseudocolour red). Nuclear DNA was labelled with DAPI (shown in blue).

Image was acquired with a confocal microscope (Leica-Microsystems TCS SP8) and a single confocal section is shown.

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

B7/21

Isotype

IgG3

Carrier free

No

Reacts with

Human

Applications

ICC

applications

Specificity

The B7/21 monoclonal antibody specifically recognizes HLA-DP antigens which are human Major Histocompatibility Complex (MHC) Class II antigens. HLA-DP antigens are heterodimers comprised of two different type I transmembrane glycoproteins that are noncovalently-associated. The ~34 kDa HLA-DP alpha (HLA-DPα) and ~26-28 kDa HLA-DP beta (HLA-DPβ) chains are encoded by HLA-DPA1 and HLA-DPB1 genes, respectively, that are located within the Human Leukocyte Antigen (HLA) Complex of chromosome 6. The B7/21 antibody recognizes a monomorphic determinant present on cells expressing HLA-DP1, -DP2, -DP3, -DP4, and -DP5 and does not reportedly bind to HLA-DR or HLA-DQ Class II antigens. HLA-DP is variably expressed on B cells, monocytes, macrophages, dendritic cells (DC), activated T cells, and tumor cell lines including B cell lines, myelomas, and some myeloid leukemias. HLA-DP functions in the presentation of peptides derived from extracellular antigens to CD4+ T cells.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICC" : {"fullname" : "Immunocytochemistry", "shortname":"ICC"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICC-species-checked": "testedAndGuaranteed", "ICC-species-dilution-info": "5 µg/mL", "ICC-species-notes": "<p></p>" } } }

Product details

Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 6.97% L-Arginine
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
See full target information HLA-DPA1

Publications (26)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 16:1558842 PubMed40406114

2025

Role of lncRNA Xist-miR-124-CCL2 axis in HIV Tat-mediated microglial activation and neuroinflammation.

Applications

Unspecified application

Species

Unspecified reactive species

Palsamy Periyasamy,Seema Singh,Abiola Oladapo,Muthukumar Kannan,Shilpa Buch

Nature communications 15:2271 PubMed38480731

2024

HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice.

Applications

Unspecified application

Species

Unspecified reactive species

Jianting Long,Xihe Chen,Mian He,Shudan Ou,Yunhe Zhao,Qingjia Yan,Minjun Ma,Jingyu Chen,Xuping Qin,Xiangjun Zhou,Junjun Chu,Yanyan Han

Nature medicine 27:2212-2223 PubMed34887574

2021

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.

Applications

Unspecified application

Species

Unspecified reactive species

Julie Westerlin Kjeldsen,Cathrine Lund Lorentzen,Evelina Martinenaite,Eva Ellebaek,Marco Donia,Rikke Boedker Holmstroem,Tobias Wirenfeldt Klausen,Cecilie Oelvang Madsen,Shamaila Munir Ahmed,Stine Emilie Weis-Banke,Morten Orebo Holmström,Helle Westergren Hendel,Eva Ehrnrooth,Mai-Britt Zocca,Ayako Wakatsuki Pedersen,Mads Hald Andersen,Inge Marie Svane

Scientific reports 10:17753 PubMed33082438

2020

Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapy.

Applications

Unspecified application

Species

Unspecified reactive species

Jeewon Lee,Joong Hyuk Sheen,Okjae Lim,Yunjung Lee,Jihye Ryu,Duckhyang Shin,Yu Young Kim,Munkyung Kim

Journal of virology 94: PubMed31915281

2020

Human Cytomegalovirus Decreases Major Histocompatibility Complex Class II by Regulating Class II Transactivator Transcript Levels in a Myeloid Cell Line.

Applications

Unspecified application

Species

Unspecified reactive species

Praneet K Sandhu,Nicholas J Buchkovich

Science translational medicine 11: PubMed31554739

2019

IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus.

Applications

Unspecified application

Species

Unspecified reactive species

Shuai Shao,Lam C Tsoi,Mrinal K Sarkar,Xianying Xing,Ke Xue,Ranjitha Uppala,Celine C Berthier,Chang Zeng,Matthew Patrick,Allison C Billi,Joseph Fullmer,Maria A Beamer,Bethany Perez-White,Spiro Getsios,Andrew Schuler,John J Voorhees,Sung Choi,Paul Harms,J Michelle Kahlenberg,Johann E Gudjonsson

Frontiers in immunology 10:1970 PubMed31481960

2019

Human Intestinal Enteroids Model MHC-II in the Gut Epithelium.

Applications

Unspecified application

Species

Unspecified reactive species

Jonathan E Wosen,Alexandra Ilstad-Minnihan,Julia Y Co,Wei Jiang,Dhriti Mukhopadhyay,Nielsen Q Fernandez-Becker,Calvin J Kuo,Manuel R Amieva,Elizabeth D Mellins

Cancer immunology, immunotherapy : CII 68:1331-1340 PubMed31317218

2019

Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade.

Applications

Unspecified application

Species

Unspecified reactive species

Jun Zhou,Jingjing Li,Indira Guleria,Tianqi Chen,Anita Giobbie-Hurder,Jonathan Stevens,Meghna Gupta,Xinqi Wu,Ryan C Brennick,Michael P Manos,F Stephen Hodi

Journal of autoimmunity 102:38-49 PubMed31054941

2019

Myelin oligodendrocyte glycoprotein revisited-sensitive detection of MOG-specific T-cells in multiple sclerosis.

Applications

Unspecified application

Species

Unspecified reactive species

Mattias Bronge,Sabrina Ruhrmann,Claudia Carvalho-Queiroz,Ola B Nilsson,Andreas Kaiser,Erik Holmgren,Caterina Macrini,Stephan Winklmeier,Edgar Meinl,Lou Brundin,Mohsen Khademi,Tomas Olsson,Guro Gafvelin,Hans Grönlund

PloS one 11:e0152384 PubMed27050553

2016

Generation of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML Technology.

Applications

Unspecified application

Species

Human

Yuya Imamura,Miwa Haruta,Yusuke Tomita,Keiko Matsumura,Tokunori Ikeda,Akira Yuno,Masatoshi Hirayama,Hideki Nakayama,Hiroshi Mizuta,Yasuharu Nishimura,Satoru Senju
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com